Merck & Co (MRK) Stock Price
Merck & Co Price
Revenue has compounded at 5.7% per year over the past 19 years to 64.93 B USD. Earnings per share have grown at 7.0% per year over the last 19 years. Merck & Co's net margin stands at 28.1%, up from 26.8% several years earlier. Merck & Co currently offers a dividend yield of about 2.20%. The payout ratio is around 45% of earnings. The dividend has grown at 4.1% per year over the past 19 years. Analysts set a median price target of 144.00 USD, implying 3.2% below the current price. Of 36 analysts, 26 rate the stock a buy — an overall Buy consensus. The stock trades about 89% above its 52-week low.
Merck & Co stock price
Merck & Co business model & stock analysis
Frequently asked questions about Merck & Co
The business model of Merck & Co Inc is centered around the development, manufacturing, and marketing of innovative pharmaceutical products and vaccines. Merck's primary aim is to improve and save lives by addressing unmet medical needs. Through rigorous research and development, the company focuses on discovering novel therapies and delivering them to patients worldwide. Merck operates across various therapeutic areas, including oncology, infectious diseases, vaccines, cardiovascular health, and more. By combining scientific expertise with a strong commitment to patients and healthcare professionals, Merck continually strives to advance medical science and make a positive impact on global health.
Merck & Co Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Merck & Co Inc in the market are Johnson & Johnson, Pfizer Inc, Novartis AG, and Bristol-Myers Squibb Company.
Merck & Co Inc is a renowned pharmaceutical company with a rich history and notable background. Established in 1891, Merck & Co Inc has been dedicated to enhancing global health and improving people's lives. The company has evolved into one of the leading players in the pharmaceutical industry, specializing in research, development, and manufacturing of innovative medications and vaccines. Merck & Co Inc has proactively contributed to medical advancements, from pioneering treatments for diseases like HIV/AIDS to addressing various health challenges. With a commitment to scientific excellence and patient well-being, Merck & Co Inc continues to shape the future of healthcare worldwide.
Merck & Co Inc, a leading pharmaceutical company, has achieved significant milestones throughout its history. The company's notable achievements include the development and launch of groundbreaking drugs like Gardasil, a vaccine for preventing cervical cancer, and Keytruda, an innovative immunotherapy for treating various types of cancer. Merck & Co Inc has also contributed to medical advancements with its research and development efforts, resulting in breakthroughs in areas such as HIV/AIDS treatment and vaccines. The company's commitment to improving global health has resulted in partnerships and initiatives aimed at tackling diseases like malaria and Ebola. Merck & Co Inc continues to make strides in the pharmaceutical industry, focusing on innovative solutions for unmet medical needs.
Merck & Co Inc is primarily present in several countries and regions across the world. The company has a strong global presence, with operations in the United States, Europe, Asia-Pacific, Latin America, and Africa. Merck & Co Inc has established a significant presence in key markets such as the United States, Germany, Japan, China, and Brazil. With its wide international footprint, Merck & Co Inc is committed to delivering its innovative healthcare solutions to patients and healthcare professionals worldwide.
Merck & Co Inc represents a strong commitment to scientific innovation, integrity, and improving global health. As a leading pharmaceutical company, Merck aims to discover, develop, and provide high-quality healthcare solutions. The company's corporate philosophy revolves around putting patients first, valuing diversity and inclusion, and taking responsibility for environmental sustainability. Merck is dedicated to delivering innovative medicines and vaccines, ensuring affordability and access for patients worldwide. With a focus on research, collaboration, and ethical business practices, Merck strives to make a positive impact on society and enhance the well-being of individuals around the globe.
Analysts currently set an average price target of 140.42 USD for the Merck & Co stock (median: 144.00 USD), implying -5.5 % versus the latest price. The consensus is based on 36 analyst ratings.
36 analysts currently rate the Merck & Co stock: 26 recommend buying, 10 holding and 0 selling. For 2026, analysts expect Merck & Co to generate revenue of 67.14 B USD and earnings per share of 2.77 USD.
Converted at the current exchange rate, the Merck & Co share trades at 130.56 EUR (148.78 USD).
The Merck & Co share (MRK) is listed on 11 stock exchanges, including: NYSE (MRK), London (0QAH.L), SIX (Zürich) (MRK1.SW), XETRA (6MK.DE), Frankfurt (6MK.F), München (6MK.MU), Düsseldorf (6MK.DU), Hamburg (6MK.HM).
Merck & Co Inc is one of the leading global pharmaceutical companies focused on the discovery, development, and marketing of drugs, vaccines, and biologics for a variety of diseases and disorders. The company is headquartered in Kenilworth, New Jersey and operates worldwide in over 140 countries.
The expected revenue of Merck & Co is 67.14 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Merck & Co is 6.88 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Merck & Co is currently 53.77. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Merck & Co stock.
The price-to-sales ratio (P/S) of Merck & Co is currently 5.51. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Merck & Co stock.
The Eulerpool Quality Score for Merck & Co is 6/10.
The ISIN of Merck & Co is US58933Y1055. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Merck & Co is A0YD8Q. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Merck & Co is MRK. The ticker symbol is used to trade Merck & Co shares on the stock exchange.
Over the past 12 months, Merck & Co paid a dividend of 3.28 USD . This corresponds to a dividend yield of about 2.20 %. For the coming 12 months, Merck & Co is expected to pay a dividend of 3.60 USD.
The current dividend yield of Merck & Co is 2.20 %.
Merck & Co pays a dividend, distributed in the months of September, December, March, June.
Merck & Co paid dividends every year for the past 36 years.
For the upcoming 12 months, dividends amounting to 3.60 USD are expected. This corresponds to a dividend yield of 2.42 %.
Merck & Co is assigned to the 'Health' sector.
In the year 2025, Merck & Co distributed 3.28 USD as dividends.
The dividends of Merck & Co are distributed in USD.
Merck & Co stock
Merck & Co Peer Group
Merck & Co Ticker
Merck & Co FIGI
All fundamentals and in-depth analysis of Merck & Co
Our stock analysis for Merck & Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merck & Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.